JP2018536638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536638A5 JP2018536638A5 JP2018519833A JP2018519833A JP2018536638A5 JP 2018536638 A5 JP2018536638 A5 JP 2018536638A5 JP 2018519833 A JP2018519833 A JP 2018519833A JP 2018519833 A JP2018519833 A JP 2018519833A JP 2018536638 A5 JP2018536638 A5 JP 2018536638A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 claims description 6
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 3
- 102100035904 Caspase-1 Human genes 0.000 claims 3
- 108090000426 Caspase-1 Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 2
- 0 C=*c(cc1)ccc1O*=* Chemical compound C=*c(cc1)ccc1O*=* 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0142929 | 2015-10-13 | ||
| KR20150142929 | 2015-10-13 | ||
| KR10-2016-0131313 | 2016-10-11 | ||
| KR1020160131313A KR101949451B1 (ko) | 2015-10-13 | 2016-10-11 | 염증성 장 질환 및 아토피 피부염 치료용 조성물 |
| PCT/KR2016/011434 WO2017065495A2 (ko) | 2015-10-13 | 2016-10-12 | 염증성 장 질환 및 아토피 피부염 치료용 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536638A JP2018536638A (ja) | 2018-12-13 |
| JP2018536638A5 true JP2018536638A5 (enExample) | 2019-11-28 |
| JP6885607B2 JP6885607B2 (ja) | 2021-06-16 |
Family
ID=58705365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519833A Active JP6885607B2 (ja) | 2015-10-13 | 2016-10-12 | 炎症性腸疾患およびアトピー性皮膚炎の処置のための組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10278931B2 (enExample) |
| EP (1) | EP3363783B1 (enExample) |
| JP (1) | JP6885607B2 (enExample) |
| KR (2) | KR101949451B1 (enExample) |
| CN (1) | CN108137490B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101949451B1 (ko) * | 2015-10-13 | 2019-05-10 | 주식회사 이노파마스크린 | 염증성 장 질환 및 아토피 피부염 치료용 조성물 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR20210042412A (ko) | 2018-09-06 | 2021-04-19 | 주식회사 이노파마스크린 | 천식 또는 파킨슨병 치료를 위한 방법 및 조성물 |
| CN118141793A (zh) * | 2022-05-17 | 2024-06-07 | 中国医学科学院基础医学研究所 | 二甲双胍及其它含胍化合物溶解夏科-莱登结晶并缓解急性肺损伤炎症中的应用 |
| CN119970807A (zh) * | 2025-03-07 | 2025-05-13 | 中国人民解放军总医院第一医学中心 | Tslp表达水平调节剂及治疗银屑病的药物和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037346A1 (en) * | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
| AU2003244132A1 (en) | 2002-07-02 | 2004-01-23 | Genox Research, Inc. | Method of examining allergic disaese and drug for treating the same |
| EP2150528A2 (en) | 2008-01-23 | 2010-02-10 | USV Limited | Process for preparation of proguanil hydrochloride |
| WO2009137100A2 (en) * | 2008-05-09 | 2009-11-12 | Tolmar, Inc. | Proguanil to treat skin/mucosal diseases |
| EP2522654A2 (en) | 2010-01-06 | 2012-11-14 | HanAll Biopharma Co., Ltd. | Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient |
| US8796338B2 (en) * | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
| NZ626578A (en) * | 2012-01-06 | 2016-11-25 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| WO2015026215A1 (ko) | 2013-08-23 | 2015-02-26 | 가톨릭대학교 산학협력단 | 바이구아나이드 유도체 화합물을 유효성분으로 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약제학적 조성물 |
| JP6462002B2 (ja) | 2014-04-29 | 2019-01-30 | ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション | 免疫疾患治療効果を有する新規化合物およびその使用 |
| WO2015167243A1 (ko) * | 2014-04-29 | 2015-11-05 | 가톨릭대학교 산학협력단 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
| KR102216701B1 (ko) | 2014-11-20 | 2021-02-18 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
| KR101949451B1 (ko) * | 2015-10-13 | 2019-05-10 | 주식회사 이노파마스크린 | 염증성 장 질환 및 아토피 피부염 치료용 조성물 |
-
2016
- 2016-10-11 KR KR1020160131313A patent/KR101949451B1/ko not_active Expired - Fee Related
- 2016-10-12 US US15/768,374 patent/US10278931B2/en active Active
- 2016-10-12 CN CN201680059836.6A patent/CN108137490B/zh not_active Expired - Fee Related
- 2016-10-12 EP EP16855712.2A patent/EP3363783B1/en not_active Not-in-force
- 2016-10-12 JP JP2018519833A patent/JP6885607B2/ja active Active
-
2017
- 2017-11-21 KR KR1020170155266A patent/KR101901895B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536638A5 (enExample) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| JP2011225596A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2020524689A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2016505050A5 (enExample) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| WO2019004788A3 (ko) | 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물 | |
| JP2019520407A5 (enExample) | ||
| JP2019524889A5 (enExample) | ||
| FI3448430T3 (fi) | Asetyylikoleeniesteraasi-inhibiittorin ja idalopirdiinin käyttö Parkinsonin taudin potilaiden kaatumisten vähentämiseksi | |
| PH12020500001A1 (en) | Non-pulsatile prolonged-release betahistine oral solid compositions | |
| IE20130078A1 (en) | Methods for using thalidomide and thalidomide analogues to maintain or increase muscle mass in treating sarcopenia | |
| JP2014162761A5 (enExample) | ||
| CA2469702A1 (en) | Darifenacin for use in the treatment of urgency induced by overactive bladder |